Shanghai Rongsheng Biopharmaceutical

Shanghai Rongsheng Biopharmaceutical is a prominent Chinese biotechnology company specializing in the research, development, and manufacturing of vaccines and in-vitro diagnostic (IVD) reagents. Founded in 1988, the company has established a significant presence in the infectious disease sector, with a commercial portfolio that includes split-virion influenza vaccines and diagnostic kits for HIV, hepatitis, and syphilis. Rongsheng operates large-scale, GMP-certified manufacturing facilities in Shanghai to support its domestic and international supply chains. The company's R&D pipeline is actively advancing next-generation vaccines for rabies and varicella through late-stage clinical trials. Despite the withdrawal of its IPO application in 2023, Rongsheng remains a key player in China's public health landscape, focusing on high-quality biological solutions for disease prevention and diagnosis.